Kathmere Capital Management LLC Has $3.20 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Kathmere Capital Management LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 5.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,148 shares of the company’s stock after buying an additional 229 shares during the period. Kathmere Capital Management LLC’s holdings in Eli Lilly and Company were worth $3,202,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bradley Foster & Sargent Inc. CT raised its stake in Eli Lilly and Company by 2.8% during the 2nd quarter. Bradley Foster & Sargent Inc. CT now owns 20,181 shares of the company’s stock valued at $18,272,000 after purchasing an additional 558 shares during the period. E Fund Management Co. Ltd. raised its position in Eli Lilly and Company by 0.9% during the second quarter. E Fund Management Co. Ltd. now owns 5,211 shares of the company’s stock valued at $4,718,000 after buying an additional 46 shares during the period. Mercer Global Advisors Inc. ADV lifted its stake in Eli Lilly and Company by 0.4% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 694,060 shares of the company’s stock worth $628,388,000 after acquiring an additional 2,681 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. boosted its position in Eli Lilly and Company by 5.7% during the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 26,527 shares of the company’s stock worth $24,017,000 after acquiring an additional 1,427 shares during the period. Finally, Tredje AP fonden grew its stake in Eli Lilly and Company by 4.6% during the 2nd quarter. Tredje AP fonden now owns 229,293 shares of the company’s stock valued at $207,597,000 after acquiring an additional 10,000 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Price Performance

NYSE LLY opened at $746.42 on Thursday. The stock has a 50-day simple moving average of $784.63 and a 200 day simple moving average of $857.48. Eli Lilly and Company has a twelve month low of $612.70 and a twelve month high of $972.53. The stock has a market capitalization of $708.59 billion, a PE ratio of 80.69, a P/E/G ratio of 2.99 and a beta of 0.41. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The business had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm’s quarterly revenue was up 20.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.10 earnings per share. Research analysts anticipate that Eli Lilly and Company will post 13.18 EPS for the current year.

Eli Lilly and Company declared that its Board of Directors has approved a stock repurchase program on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to purchase up to 2% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be issued a dividend of $1.50 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.80%. Eli Lilly and Company’s payout ratio is presently 64.86%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on LLY shares. Wolfe Research assumed coverage on shares of Eli Lilly and Company in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price target for the company. Barclays decreased their target price on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research note on Thursday, October 31st. Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Bank of America reissued a “buy” rating and set a $997.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Finally, Truist Financial upped their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $1,002.22.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.